Ethical Challenges in Biomarker-Driven Drug Development

The author reviews ethical challenges arising from the increasing use of biomarkers in drug development, including concerns about informed consent for biospecimen use, the justice implications of precision medicine increasing drug costs and limiting access, and a novel challenge relating to the “principle of efficiency” requiring studies to maximize their contribution to knowledge.